NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on tough lung cancer mutation
Disease control Not yet recruitingThis phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly a…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, …
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis trial tests a new approach for people with early-stage non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of targeted radiation (SBRT), two immunotherapy drugs (iparomlimab and tuvonralimab, also called QL1706), and ch…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can chemo stop immunotherapy from backfiring in lung cancer?
Disease control Not yet recruitingThis study looks at people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Some patients experience rapid tumor growth when treated with immunotherapy alone. The trial will test whether adding chemotherapy to the immunotherapy drug cemiplimab can pre…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill takes on hard-to-treat lung cancer in major trial
Disease control Not yet recruitingThis study tests a new targeted drug, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 472 adults who have already tried at least one prior treatment will be randoml…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail aims to tackle resistant lung cancer
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long th…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
Can a morning light session boost immunotherapy? small trial aims to find out
Symptom relief Not yet recruitingThis pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Lung cancer immune markers under the microscope
Knowledge-focused Not yet recruitingThis observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new d…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:25 UTC